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Cardiotrophin-1 (CT-1) produces longitudinal elongation of neonatal cardiomyocytes, but its effects in adult cardiomyocytes are not known.
Recent observations indicate that CT-1 may be involved in pressure overload left ventricular hypertrophy (LVH). We investigated whether the
hypertrophic effects of CT-1 are different in cardiomyocytes isolated from adult normotensive and spontaneously hypertensive rats (SHR).
Hypertrophy was evaluated by planimetry and confocal microscopy, contractile proteins were quantified by Western blotting and real-time RT-
PCR, and intracellular pathways were analyzed with specific chemical inhibitors. CT-1 increased c-fos and ANP expression (p<0.01) and cell area
(p<0.01) in cardiomyocytes from both rat strains. In Wistar cells, CT-1 augmented cell length (p<0.01) but did not modify either the transverse
diameter or cell depth. In SHR cells, CT-1 increased cell length (p<0.05), cell width (p<0.01) and cell depth, augmented the expression of myosin
light chain-2v (MLC-2v) and skeletal α-actin (p<0.01) and enhanced MLC-2v phosphorylation (p<0.01). The blockade of gp130 or LIFR
abolished CT-1-induced growth in the two cell types. All distinct effects observed in cardiomyocytes from SHR were mediated by STAT3.
Baseline angiotensinogen expression was higher in SHR cells, and CT-1 induced a 1.7-fold and 3.2-fold increase of angiotensinogen mRNA in
cardiomyocytes from Wistar rats and SHR respectively. In addition, AT1 blockade inhibited the specific effects of CT-1 in SHR cells. Finally, ex
vivo determinations revealed that adult SHR exhibited enhanced myocardial CT-1 (mRNA and protein, p<0.01), increased cell width (p<0.01)
and concentric LVH compared with pre-hypertensive SHR. These findings reveal a specific cell-broadening effect of CT-1 in cardiomyocytes from
adult SHR and suggest that the hypertensive phenotype of these cells may influence the hypertrophic effects of CT-1, probably by means of an
exaggerated induction of angiotensinogen expression. We suggest that CT-1 might facilitate LVH in genetic hypertension through a cross-talk with
the renin–angiotensin system.
© 2006 Elsevier Inc. All rights reserved.Keywords: Adult cardiomyocytes; Angiotensinogen; Cardiac hypertrophy cardiotrophin-1; Hypertension; Myofibrils; Sarcomere; STATs1. Introduction
Left ventricular hypertrophy (LVH) is the first compensatory
mechanism that the overloaded myocardium employs to
maintain its normal function, and in the case of hypertensive
heart disease it is an independent predictor of cardiovascular
events. Pathological perpetuation of pressure overload together
with non-hemodynamic factors promotes an early adaptative
increase in wall thickness (concentric hypertrophy), normally
followed by the reduction in myocardial distensibility and the⁎ Corresponding author. Tel.: +948 19 47 00x3023; fax: +948 19 47 16.
E-mail address: fortuto@unav.es (M. Antonia Fortuño).
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doi:10.1016/j.yjmcc.2006.03.433development of dilated cardiomyopathy and heart failure [1]. At
cellular level, the growth of cardiomyocytes is the main
determinant of LVH, although other factors such as exaggerated
collagen accumulation are also involved [2,3]. Recent experi-
mental and clinical evidence indicates that interleukin-6-related
cytokines may participate in the development of hypertensive
LVH [4–6].
Cardiotrophin-1 (CT-1) is a member of interleukin-6 (IL-6)
family of cytokines that exerts its cellular effects by interacting
with the heterodimer constituted by the glycoprotein 130
(gp130) and the leukemia inhibitory factor receptor β (LIFR)
[7]. In terminally differentiated cardiomyocytes, activation of
ERK1/2 and PI3K/Akt pathways results in cell protection
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was first cloned from embryoid bodies as a 21.5 kDa protein
capable to induce hypertrophy in neonatal cardiomyocytes [10].
Subsequent studies confirmed these observations showing the
involvement of signal transducers and activators of transcription
(STATs) as the main signaling pathway [11]. In addition,
hypertrophy induced by CT-1 in neonatal cardiomyocytes
exhibits a longitudinal morphometry and a distinct molecular
pattern compared to α-adrenergic stimulation [12]. The in vitro
studies performed in neonatal cells suggesting a role for the
cytokine in cardiac hypertrophy are further supported by several
in vivo observations. First, intraperitoneal administration of
recombinant CT-1 to normotensive mice increases left ventricle
weight in a dose-dependent manner, although the geometric
pattern of hypertrophy has not been determined [13]. Moreover,
left ventricular CT-1 expression is increased in different
experimental models of hypertensive LVH [5,14]. In addition,
an association between LVH and high plasma levels of CT-1 has
recently been observed in essential hypertensive patients [6].
Furthermore, regression of LVH and diminution of plasma
levels of CT-1 are associated in treated hypertensive patients
[15]. However, the hypertrophic effects of CT-1 in adult car-
diomyocytes have not been investigated.
The aim of this study was to characterize the hypertrophic
effects of CT-1 in adult cardiomyocytes and to investigate
whether CT-1-induced hypertrophy is influenced by the
hypertensive phenotype of cells. Thus, hypertrophic effects of
the cytokine were analyzed in cardiomyocytes isolated from
adult normotensive (Wistar) and spontaneously hypertensive
rats (SHR). We also investigated the myocardial expression of
CT-1 in adult SHR before and after the development of LVH.
2. Methods
2.1. Animals
The investigation was performed in accordance with the
Guide for Care and Use of Laboratory Animals published by
the US National Institutes of Health (NIH Publication no. 82-
23, revised in 1996). Animals were provided by Harlam UK
Limited (Bicester, England). All rats were housed in individual
cages and were fed a standard rat chow and tap water ad
libitum. They were maintained in a quiet room at constant
temperature (20 to 22 °C) and humidity (50 to 60%). For the
study with isolated cardiomyocytes, Wistar rats and SHR
weighting 200–250 g were sacrificed by decapitation under
anesthesia i.p. with Ketamine 75 mg/kg (Imalgene 1000,
Merial) and Xilacine 5 mg/kg (Rompun, Bayer), and the hearts
were rapidly excised for cardiomyocytes isolation. For ex vivo
determinations, 6-week-old SHR (Control group, N=20) and
30-week-old SHR (N=20) were employed. Systolic blood
pressure was measured by the standard tail-cuff method using a
LE 5007 Pressure Computer (Letica Scientific Instruments).
Animals were sacrificed by the protocol described above.
Hearts were extracted, weighted and rapidly frozen in liquid
nitrogen for molecular studies or fixed by immersion in 4%
buffered formalin for 24 h and embedded in paraffin formorphometric determinations. Hence, systolic cardiac dimen-
sions were computed by Image Analysis as described below.
2.2. Adult cardiomyocyte isolation and culture
Primary cultures of adult cardiomyocytes were obtained as
recently described [9]. Briefly, the hearts were perfused on a
Langerdorff system at 37 °C with a calcium-free buffer
(115 mmol/L NaCl, 2.6 mmol/L KCl, 1.2 mmol/L MgSO4,
1.2 mmol/L KH2PO4, 6 mmol/L NaHCO3, 11 mmol/L
glucose (D+), pH 7.3) and Collagenase A (Boehringer–
Mannheim) at 0.2% (w/v). Left ventricles were minced into
small pieces in oxygenated perfusion buffer with BSA 1.3%
and trypsin 0.025% and then centrifuged at 50×g for 5 min.
Following the enrichment step with 4% BSA, cells recovered
from the pellet consisted of 90% rod-shaped viable
cardiomyocytes. The average number of cardiomyocytes
obtained was 2.5×106. Cells were plated in laminin-pre-
coated (0.5 μg/cm2) culture plates at a density of 104 cells/
cm2 in serum-free medium 199 with Hanks' salts supple-
mented with 26 mmol/L NaHCO3, 10
−4 mmol/L insulin,
5 mmol/L creatinine, 2 mmol/L L-carnitine, 0.2% BSA,
10− 5 mmol/L Ara-C, 5 mmol/L taurine, 100 IU/mL
penicillin, 0.1 mg/mL streptomycin, 10 mmol/L N-(2-hydro-
xyetil) piperazine-N′2-etanolsulfonic acid (HEPES), pH 7.4.
After 4 h of pre-incubation, attached cells were incubated
overnight with fresh medium until treatments.
CT-1 (R&D Systems) was incubated at 10−9 mol/L for 48 h
for hypertrophy assessment, 24 h for protein investigation and
3 h for mRNA analysis. To investigate the intracellular
pathways involved in the CT-1 effect, the following inhibitors
were added 1 h prior to addition of CT-1: PI3K inhibitor
Wortmannin at 10−6 mol/L (Calbiochem), the MAPK inhibitor
PD98059 at 10−6 mol/L to inhibit ERK1/2 and at 30.
10− 6 mol/L to inhibit ERK5 (Calbiochem), the STATs
inhibitor AG490 at 10−6 mol/L (Calbiochem), antibodies
against LIFR (Santa Cruz) and gp130 (Santa Cruz) at
10−6 mol/L. In some experiments, cells from SHR were pre-
incubated and co-incubated with the angiotensin II AT1
receptor antagonist losartan at 10−6 mol/L.
2.3. Image analysis
For planimetry, isolated cells were grown in glass-covered
2 cm2 wells. After treatments, cells were fixed for 30 min in 4%
formalin on ice and maintained on 70% ethanol at −20 °C until
analysis. Cell area, length and width were quantified in triplicate
in a minimum of 250 cardiomyocytes per experimental
condition from at least 3 different rats. After digitalization at
200× magnification in an image analysis system (Soft Imaging
System Analysis), cell area was calculated from the cell
perimeter drawn with the mouse, cell length and cell width
were drawn in triplicate as the longest and shortest axis of the cell
respectively and the average was recorded. All measurements
were calibrated with known standards. Myocardial determina-
tions in cardiac tissue from 6- and 30-week-old SHR were
performed in 6-μm-thick sections stained with hematoxylin for
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cardiomyocyte diameter. Each parameter was measured in
triplicate. For cell width, at least 20 cardiomyocytes per section
were measured.
2.4. Confocal microscopy
Cardiomyocytes in culture assume a cross-sectional area
(CSA) that resembles a flattened ellipse. To investigate the shape
changes of cardiomyocytes in 3D cells were stained with FITC
(1 μg/mL) for 30 min at room temperature, washed five times in
PBS and analyzed on a laser scanning confocal microscope
(LSM 510, Carl Zeiss). Twenty cardiomyocytes per experi-
mental condition were examined to obtain cell area, length and
width in the X/Y plane and to analyze the CSA by means of 3D
reconstruction of the cellular planes 1-μm-thick scanned in the Z
axis. In the CSA, visualized by rotating the entire reconstructedFig. 1. (A) 3D reconstruction of an entire cardiomyocyte from 1 μm-thick plane scan
cell around the central axis. (B) α-actinin staining allowed visualizing the Z line loc
length of 15 sarcomeres per cardiomyocyte was measured.cell around its central axis (Fig. 1A), the two diameters were
computed in triplicate (M and m). Assuming an elliptical cross-
section, the area of CSAwas calculated as CSA=π (M / 2) (m / 2).
Cell volume was calculated: V=CSA×length.
2.5. Assessment of sarcomeres length
For immunostaining, cells were plated in glass-covered
2 cm2 wells. Sarcomeres were visualized by immunostaining of
the Z-band α-sarcomeric actinin. Cells were fixed for 15 min at
37 °C in 3% formaldehyde. Mouse anti-α-sarcomeric actinin
antibody (Sigma) was incubated for 1 h at 1:1000 in PBS and
CY3-conjugated sheep anti-mouse secondary antibody (Sigma)
was added for 30 min at 1:1000. After washing, cells were
mounted in 4′-6-diamino-2 phenylindole (DAPI)-containing
medium (Vectashield). Twenty cells per condition were
captured in an epifluorescence inverted microscope and thened in the Z axis. Panels show the images obtained by rotating the reconstructed
ated at the end of sarcomeres. Twenty cells per condition were captured and the
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Soft Imaging System Analysis.
2.6. Myofibrillar protein extraction and silver staining
Myofibrillar proteins were extracted as described by Arrel
et al. [16] with minor modifications. After the specific
treatments, cells were washed in PBS and harvested in 50 μL
of HEPES extraction buffer consisting of (in mmol/L): HEPES
25 (pH 7.4), NaF 50, Na3VO4 0.25, phenylmethylsulfonyl
fluoride 0.25, EDTA 0.5 and 1 tablet of protease inhibitors
cocktail (Boehringer Mannheim) per 50 mL of buffer. After
centrifugation, supernatants containing the cytosolic fraction
were discarded and the remaining pellet was subjected to further
extraction by two rounds of homogenization in 25 μL of acid
extraction buffer, consisting of 1% vol/vol trifluoroacetic acid
(TFA) and 1 mmol/L Tris (2-carboxyethylphosphine) hydro-
chloride (pH 2). Supernatants were kept at −80 °C until use.
Aliquots of 5 μg of proteins were size fractionated by vertical
SDS-PAGE with 15% acrylamide (200:1 acrylamide–bisacry-
lamide ratio, pH 9.3), and the resulting gels were silver stained
according to Pharmacia Biotech's instructions. Gels were fixed
in acetic acid, washed, silver stained and scanned using an
image densitometer.
2.7. Western blotting
For Western blot assays, cardiomyocytes were cultured in
10 cm2 plates. Aliquots of 20 μg of myofibrillar proteins were
size fractionated on 15% (for MLC-1, MLC-2v, MLC-2-P,
Troponin I and Troponin T), 12% (for p42/44 and p42/44-P)
or 10% (for PI3K, PI3K-P, Akt, Akt-P, ERK5, ERK-5-P,
sarcomeric α-actin and skeletal α-actin), 7.5% (for STAT-3,
STAT-3-P, MHC-α, MHC-β and sarcomeric α-actinin) poly-
acrylamide gels by electrophoresis. The following specific
antibodies were employed: MLC-1 at 1:10,000 (Abcam),
MLC-2v at 1:5 (Biocytex), MLC-2v-P at 1:500 (Santa Cruz
Biotechnology), Troponin I at 1:1000 (Cell Signaling),Table 1
Hypertrophic effects of CT-1 in cardiomyocytes isolated from adult Wistar rats and
WISTAR
Baseline CT-1
ANP 0.97±0.37 3.42±0.48 <
c-fos 7.44±2.71 19.26±2.01 <
Image analysis
Cell area (μm2) 1796±40 2161±26 <
Cell length (μm) 69.9±1.3 86.4±1.71 <
Cell width (μm) 25.6±0.4 25.7±0.4 n
Confocal microscopy
Cell area (μm2) 1391±48 1551±71 <
Cell length (μm) 69.7±2.6 76.2±2.5 <
Cell width (μm) 22.7±1.3 22.5±1.1 n
CSA (μm2) 495±34 521±48 n
M (μm) 27.98±0.91 28.69±0.95 n
m (μm) 22.71±0.78 22.85±1.48 n
Volume (μm3) 35,792±3221 41,277±3143 <
a p<0.01 vs. Wistar baseline. CSA: cross-sectional area. M: major axis of CSA. mTroponin T at 1:1000 (Hytest), p42/44 1:2000 (Cell Signal-
ing), p42/44-P (Thr202/Tyr204) at 1:4000 (Cell Signaling),
PI3K at 1:1000 (Cell Signaling), PI3K-P (Tyr) at 1:1000 (Cell
Signaling), Akt at 1:1000 (Cell Signaling), Akt-P (Ser473) at
1:1500 (Cell Signaling), ERK-5 at 1:1000 (Cell Signaling),
ERK-5-P (Thr218/Tyr220) at 1:1000 (Cell Signaling), STAT-
3 at 1:1000 (Cell Signalling), STAT-3-P (Ser727) at 1:1000
(Cell Signalling), sarcomeric α-actin at 1:10000 (Sigma),
skeletal α-actin at 1:500 (Lab Vision), MHC-α at
1:200 (Covance Research), MHC-β at 1:500 (Covance
Research), sarcomeric α-actinin at 1:5000 (Sigma) and CT-1
at 1:2000 (a gift from Dr. Martinez). In all cases, bound
antibody was detected by peroxidase-conjugated secondary
antibodies (Amersham Biosciences) and visualized using the
ECL-Plus chemiluminescence detection system. After densito-
metric analyses, optical density values were expressed as
arbitrary units (AU).
2.8. Reverse transcription and real-time PCR
Total RNA was extracted from myocytes using Trizol
(Invitrogen) (1 mL/10 cm2 dishes) and subsequently purified
using QIAGEN's RNeasy Total RNA Isolation kit. Reverse
transcription was performed with 250 ng of total RNA. Real-
time PCR was performed with an ABI PRISM 7000 Sequence
Detection System by using specific TaqMan MGB fluorescent
probes (Applied BioSystems). Constitutive 18S ribosomal RNA
was used as endogenous control. For the relative quantitative
analysis of unknown samples, two calibration curves were
prepared for both the target and the endogenous reference,
representing Ct values as a function of the log amount of
starting material. For each experimental condition, the mean
quantity of target gene and endogenous control was obtained
from the appropriate standard curve in triplicate. The SD among
these triplicates was always <0.2. The mean value of target was
divided by the mean value of the endogenous control to obtain a
normalized mean quantity per sample or experimental
condition.SHR
SHR
p Baseline CT-1 p
0.01 2.06±0.89 8.12±0.94 <0.01
0.01 9.46±1.20 23.80±3.15 <0.01
0.01 2520±131a 3031±150 <0.01
0.01 87.0±3.5a 93.1±3.4 <0.05
.s. 32.8±1.6a 37.7±2.08 <0.01
0.05 2197±145a 2976±182 <0.01
0.05 87.71±3.85a 97.14±4.8 <0.05
.s. 27.4±1.1a 34.85±1.35 <0.01
.s. 681±65a 846±49 <0.01
.s. 34.08±1.79 39.56±1.50 <0.05
.s. 24.98±1.20 27.11±0.90 <0.05
0.05 60,033±7696a 82,520±5655.77 <0.01
: minor axis of CSA.
Fig. 2. CT-1 increased the expression of the shown contractile proteins from the thick filament (A), the thin filament (B) and the Z-band (C) of sarcomere in a similar fashion in cells from Wistar and SHR. On the
contrary, CT-1 increased MLC-2v and phosphorylated MLC-2v (D) as well as skeletal α-actin (E) only in SHR cells. A representative Western blot and the histogram with bars representing the mean±standard error
of the ratio protein to β-actin obtained in three independent experiments and rats are shown for each protein. Each Western was performed at least in duplicate. (F) CT-1 increased the mRNA expression of MLC-2v
and α-skeletal α-actin only in cells from SHR. The normalized mean values of the target gene are plotted. Bars represent the mean±standard error of three independent experiments and rats. *p<0.01 vs. baseline.
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Results are presented as mean±standard error, computed from
the average measurements obtained from each group of cells or
from each group of animals. Normal distribution of data was
checked bymeans of the ShapiroWillks test. A Levene statistic test
was performed to check the homogeneity of variances. Differences
among more than 2 experimental conditions were tested by the
ANOVA one way test followed by the Scheffé test to analyze
differences between groups. The unpaired Student's t test or the
Mann–Whitney U test was used to assess statistical differences
between two experimental conditions and between 6- and 30-week-
old SHR. P values lower than 0.05 were considered significant.
3. Results
3.1. CT-1 induces different morphometric patterns of
hypertrophy in cardiomyocytes from Wistar rats and SHR
Hypertrophic effects of CT-1 are summarised in Table 1.
Compared with cells from Wistar rats, cardiomyocytes isolatedFig. 3. Cell area (A), length (B) and width (C) were determined by planimetry after p
with CT-1 for 48 h. Values represent the mean±standard error of a minimum of 12
performed in three rats yielded identical results. *p<0.01 vs. baseline; $p<0.01 vs.from SHR exhibited enhanced baseline expression of ANP and
c-fos mRNA expression (p<0.05) and greater cell area
(p<0.01), cell width (p<0.01) and cell length (p<0.01) assayed
by means of both conventional image analysis and confocal
microcopy. Baseline CSA and cell volume determined by
confocal microscopy were also higher in cells from SHR
(p<0.01). Incubation with CT-1 resulted in the increase of ANP
and c-fos, cell area and length in the two cell types. However, cell
width, assayed by image analysis or confocal microscopy, and
cell depth and CSA determined by confocal microscopy were
augmented by CT-1 only in SHR cells (Table 1). Similar results
were found in cardiomyocytes isolated from Wistar and SHR
with different ages (from 6 to 25 weeks old), suggesting that the
specific morphometry observed in SHR cardiomyocytes did not
depend on the baseline cardiomyocyte size (data not shown).
Visualization of sarcomeric Z-bands by α-sarcomeric actinin
staining (Fig. 1B) allowed determining sarcomere length to
verify that CT-1 did not modify this parameter (baseline: 2.49±
0.08 μm, CT-1: 2.48±0.02 μm). These experiments were
performed in cells from Wistar rats, given that they exhibited
the highest elongation response.re-incubation for 1 h with antibodies specific for gp130 or LIFR and incubation
0 cardiomyocytes per experimental condition. Three independent experiments
CT-1 without antibody.
Fig. 4. Cardiomyocytes were incubated with CT-1 for the indicated times.
Proteins from Wistar rats and SHR cardiomyocytes were analyzed in the same
membrane. Images are representative of three independent experiments, and
histograms bars represent the mean±standard error of the three independent
experiments performed with three rats. *p<0.01 vs. CT-1 baseline (0 min);
$p<0.05 vs. Wistar activation.
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protein expression in cardiomyocytes from Wistar rats and
SHR
Silver-stained gels of high-abundance proteins illustrated
that CT-1 promoted a different pattern of contractile protein
expression in Wistar rats and SHR cardiomyocytes (data not
shown). Thus, CT-1-induced changes in the expression of the
main contractile proteins were assayed by Western blotting in
cardiomyocytes from the two strains. Panels A–C in Fig. 2
show that CT-1 enhanced (p<0.05) in a similar manner the
expression of α- and β-MHC, MLC-1, sarcomeric α-actin,
Troponins I and T and sarcomeric α-actinin in cardiomyocytes
isolated fromWistar rats and SHR. In contrast, CT-1 augmented
(p<0.01) the amount of MLC-2v, phosphorylated MLC-2v and
skeletal α-actin only in cardiomyocytes from SHR, while no
changes were observed in cells from Wistar rats (Fig. 2D, E).
The analysis of mRNA expression by real-time RT-PCR
confirmed that the specific changes in these proteins were
produced at transcriptional level since both MLC-2v and
skeletal α-actin mRNAs were significantly augmented by CT-1
in SHR cells (p<0.01) (Fig. 2F).
3.3. Signaling pathways mediating CT-1 hypertrophic
responses in cardiomyocytes from Wistar rats and SHR
We further explored the origin of the distinct CT-1 effects
observed in SHR cells by analyzing the signaling pathways
triggered by the cytokine. To investigate the involvement of
gp130/LIFR heterodimer, cardiomyocytes from the two strains
were incubated with specific antibodies against the two
subunits prior to the addition of the cytokine. As illustrated in
Fig. 3, the presence of any of the two antibodies abolished
(p<0.01) the increment in cell area and length induced by CT-1
alone in cells from the two strains of rats, and it also abrogated
the increment in cell width observed in cardiomyocytes from
SHR. The quantitative analysis of gp130 and LIFR mRNA and
protein in cardiomyocytes from Wistar rats and SHR demon-
strated a similar expression of these molecules in the cells from
the two strains of rats (data not shown). Phosphorylation
assessment of the main known CT-1 intermediates demon-
strated an enhanced baseline activation of STAT3 and ERK5 in
cardiomyocytes from SHR compared to cells from Wistar rats
(p<0.01) (Fig. 4). Incubation with CT-1 promoted the
phosphorylation of the five signaling substrates analyzed
(PI3K, Akt, p42/44, STAT3 and ERK5) in the two groups of
cardiomyocytes (Fig. 4), indicating that CT-1 activates the same
intracellular pathways in cells from the two strains of rats. The
higher (p<0.01) increase in STAT3 and ERK5 phosphorylation
observed in SHR cardiomyocytes might be due to the enhanced
baseline phosphorylation observed in these substrates. To study
the involvement of these signaling pathways in CT-1-induced
hypertrophy, specific chemical inhibitors were added to the
culture medium prior to the addition of the cytokine. As shown
in Fig. 5, both MEK5 inhibition with PD98059 30 μmol/L and
STAT3 inhibition with AG490 abolished (p<0.01) the incre-
ment in cell area and length induced by CT-1 in Wistar rats andSHR cells. In contrast, only AG490 blunted (p<0.05) the
increase in transverse diameter observed in SHR cells. Neither
PI3K inhibition with Wortmannin nor p42/44 inhibition with
PD98059 1 μmol/L affected the hypertrophic effects of CT-1.
None of the chemical inhibitors employed modified cardiomyo-
cyte dimensions when incubated alone (data not shown). As
shown in Fig. 6A, the increase in MLC-2v and skeletal α-actin
induced by CT-1 in SHR cardiomyocytes was abrogated by
AG490, indicating that STAT3 mediated this specific effect in
these cells. The induction of angiotensinogen mRNA expression
by CT-1 via STAT3 has been previously reported in neonatal
cardiomyocytes [17], but this effect had not been tested in adult
cells. Given that the distinct response observed in SHR cells
appeared to be mediated by STAT3 pathway, we compared the
Fig. 5. Cells were pre-incubated with the indicated chemical inhibitors for 1 h and then with CT-1 for 48 h. Cell area (A), length (B) and width (C) were determined by
planimetry. Values represent the mean±standard error of a minimum of 120 cardiomyocytes per experimental condition. Three independent experiments performed in
three rats yielded identical results. **p<0.01 vs. baseline; *p<0.05 vs. baseline; $$p<0.01 vs. CT-1; $p<0.05 vs. CT-1.W,Wortmannin; PD1, PD98059 at 10−6 mol/L
to inhibit p42/44; PD30, PD98059 at 30×10−6 mol/L to inhibit ERK-5; AG, AG490.
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the two strains of rats. Fig. 6B illustrates that cardiomyocytes
from SHR exhibited higher (p<0.01) baseline expression of
angiotensinogen compared to cardiomyocytes from Wistar rats.
CT-1 induced a 1.7-fold increase (p<0.01) in cells from Wistar
rats and a 3.2-fold increase (p<0.01) in cells from SHR. Hence,
angiotensinogen expression after CT-1 incubation was 3.8-fold
increased in SHR cardiomyocytes compared to cells fromWistar
rats. Finally, co-incubation of SHR cardiomyocytes with CT-1
and losartan inhibited the increase in angiotensinogen expres-
sion, cell width and MLC-2v and skeletal-α-actin expression
induced by CT-1 alone in these cells (Fig. 7).
3.4. Myocardial expression of CT-1 is associated with
cardiomyocyte growth and left ventricular hypertrophy in SHR
To study whether the differential hypertrophic effect
observed in SHR cardiomyocytes had a relevance in vivo,
myocardial expression of CT-1, cardiomyocyte width and left
ventricle geometry were assayed in 6- and 30-week-old SHR.Compared with young animals, 30-week-old SHR exhibited
enhanced blood pressure (233±4 vs. 180±4 mm Hg, p<0.01)
and cardiac weight (1.9±0.01 vs. 0.46±0.02 g, p<0.01).
Myocardial expression of CT-1 mRNA and protein was
augmented (p<0.01) in 30-week-old SHR compared to 6-
week-old SHR (Fig. 8A). Transverse diameter of cardiomyo-
cytes was significantly increased in 30-week-old SHR com-
pared with 6-week-old SHR (46.1±1.5 μm vs. 27.0±0.9 μm,
p<0.01). The ratio left ventricular wall thickness to left
ventricular chamber diameter was 1.7-fold higher (p<0.01) in
30-week-old SHR compared with 6-week-old SHR (Fig. 8B).
Similarly, the ratio left ventricular cross-sectional area to left
ventricular chamber area was 2.4-fold increased (p<0.01) in 30-
week-old SHR compared to 6-week-old SHR. These data
indicate that SHR developed concentric LVH.
4. Discussion
The main findings of the current study are the following:
first, CT-1 promotes longitudinal elongation of normal adult
Fig. 6. (A) SHR cardiomyocytes were pre-incubated for 1 hwith the STAT3 blocker AG490 and thenwith CT-1 for 24 h. A representativeWestern blot and the histogram
with bars representing the mean±standard error of three independent experiments are shown for each protein. *p<0.01 vs. baseline and CT-1+AG. AG, AG490 (B)
Angiotensinogen mRNAwas assayed in cardiomyocytes from Wistar rats and SHR before and after 3 h incubation with CT-1. Bars represent mean±standard error of
triplicates in three independent experiments. $p<0.01 vs. baseline; *p<0.01 vs. CT-1.
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STAT3 andMEK5. Second, in cardiomyocytes from adult SHR,
CT-1 specifically augments cell length and width, the expres-
sion of MLC-2v and skeletal α-actin and the phosphorylation
degree of MLC-2v. All these actions are mediated by STAT3
signaling cascade. Third, the distinct effects observed in SHR
cardiomyocytes are associated with the higher CT-1-induced
angiotensinogen expression detected in these cells, and they are
inhibited by the AT1 receptor antagonist losartan. Finally, an
exaggerated expression of myocardial CT-1 is temporally
associated with cardiomyocyte widening during the develop-
ment of concentric hypertrophy in SHR.Fig. 7. SHR cardiomyocytes were pre-incubated for 1 h with the AT1 blocker
losartan and then with CT-1 for 24 h (A) or 3 h (B) and (C). Cell width was
assayed by planimetry, and mRNA expression of the indicated genes was
assayed by real-time RT-PCR. The normalized mean values of the target
genes are plotted in (B) and (C). Bars represent the mean±standard error of
three independent experiments performed in three rats. *p<0.01 vs. baseline
and CT-1+Los.Current data in cells from Wistar rats are the first evidence
showing that CT-1 induces a longitudinal pattern of enlarge-
ment together with the absence of changes in the expression of
skeletal α-actin and MLC-2v in adult cardiomyocytes. The
observation that CT-1 does not modify the length of sarcomeres
indicates that the increase in cell length results from the addition
of new myofibrils in series. These findings are in accordance
with previous studies performed in neonatal cells by Wollert et
al. [12]. We also show that the blockade of STAT3 or MEK5
blunts the hypertrophic effect of CT-1. The involvement of
MEK5 in CT-1-induced longitudinal elongation has been
recently reported in neonatal cardiomyocytes [18], and it is
further supported by the molecular observation that over-
expression of activated MEK5 induces serial insertion of
sarcomeres in neonatal cardiomyocytes in vitro and eccentric
cardiac hypertrophy in vivo [19]. With regard to the STAT3
pathway, although it is reportedly involved in neonatal
cardiomyocyte hypertrophy induced by CT-1 [11] and other
IL-6-related cytokines [4], its role has been recently questioned
by other authors in the same cell type [18]. Interestingly, STAT3
upregulates MEK5 in other cell types [20]. Thus, the possibility
that STAT3 mediates the longitudinal elongation through the
downstream activation of MEK5, which determines the serial
assembly of sarcomeres, requires further investigations.
The main finding in the present study is the distinct effect of
CT-1 observed in SHR cardiomyocytes. The most important
determinant of LVH in SHR is the transverse growth of
cardiomyocytes, which has been previously reported both in
cardiac tissue and in isolated cells [21,22]. Similarly, other
groups have demonstrated an increase mRNA expression of the
contractile protein MLC-2v [23,24] and the embryonic gene
skeletal α-actin [25] in this experimental model. Several
cardiomyocyte growth factors, including endothelin, angioten-
sin II and α-adrenergic stimulation, upregulate the expression of
Fig. 8. (A) The expression of CT-1 was determined in myocardium from 6-week-old SHR (SHR-6, N=10) and 30-week-old SHR (SHR-30, N=10). A representative
Western blot and PCR are shown in the upper panels, and the histogram bars represent mean±standard error in each group. (B) Left ventricle morphometry and
cardiomyocyte transverse diameter were assayed in 6 μm tissue sections stained with hematoxylin and Masson trichrome respectively. All parameters were determined
in triplicate. For cardiomyocyte width, at least 20 cells per section were measured. Representative tissue sections employed for left ventricular morphometry and
cardiomyocyte diameter analysis are shown in the upper panels. Histogram bars represent the mean±standard error obtained in the two groups of animals (N=10).
LVWT: left ventricle wall thickness; *p<0.01 vs. 6-week-old SHR.
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data suggest that CT-1 is a new specific cellular inducer of SHR
cardiomyocyte growth and, hence, a new potential mediator of
LVH in hypertension. Of special interest is the observation that
CT-1 increases MLC-2v phosphorylation. Phosphorylated
MLC-2v activates the contraction in smooth muscle and
modulates force production in striated muscle. Several
biochemical studies have demonstrated that this chemical
modification, which produces a change in charge affecting the
amino-terminus of the protein, potentiates productive interac-
tions of the myosin head with the actin filament and leads to
increased calcium sensitivity [33]. In addition, the observation
that transgenic mice expressing non-phosphorylable MLC-2v in
the ventricle develop cardiac dilatation suggests a role for this
modification of MLC-2v in normal cardiac development and
maintenance [34]. Interestingly, phosphorylation of MLC-2v by
MLC kinase has been reported to mediate sarcomere organiza-
tion in neonatal cardiomyocytes in response to hypertrophic
agonists [35], however, its role in the insertion of sarcomeres
that account in the adult cell has not been investigated. The
precise involvement of phosphorylated MLC-2v in thetransverse growth of adult cardiomyocytes and the pathophy-
siological meaning of this molecule in pressure overload LVH
should be further studied.
The question arises as to the molecular mechanisms
determining the distinct CT-1 effects observed in SHR cells.
Current data comparing the signaling cascade triggered by
CT-1 show that the cytokine activates by phosphorylation the
same intracellular pathways in cardiomyocytes from Wistar
rats and SHR. Moreover, in both cases, hypertrophy is
induced via gp130/LIFR heterodimer and involves the same
downstream cascades, namely STAT3 and MEK5 mediating
the increase in cell area and length size. Finally, the
expression of gp130 and LIFR is similar in cells from the
two strains of rats. Taken together, these results indicate that
the specific response of cardiomyocytes from SHR to CT-1
may be downstream the mediators here analyzed. The
observation that all the specific effects found in SHR are
abolished by the STAT3 inhibitor AG490 suggests a role of
this signaling cascade in the distinct response of these cells.
STATs are transcription factors that mediate cytokine and
growth factor-induced gene transcription. Ligand binding to
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ylates in tyrosine the STAT3 located in the cytoplasm.
Activated STAT3 translocates to the nucleus, binds to specific
DNA response sequences and triggers the expression of target
genes. A growing line of evidence has implicated the gp130
activation of JAK/STAT cascade in pressure overload cardiac
hypertrophy [36,37]. Specifically, CT-1 increases angiotensi-
nogen promoter activity and mRNA expression in rat
cardiomyocytes through STAT3 phosphorylation and subse-
quent binding to the specific St-domain [17]. Interestingly, the
St-binding activity of STAT3 is dramatically increased in
hypertrophied hearts from adult SHR, probably because of the
local activation of renin–angiotensin system that accounts in
this model since angiotensin II injection in vivo mimics the
enhanced St-binding activity of STAT3 observed in the
myocardium of SHR [38]. Current results showing enhanced
STAT3 phosphorylation and angiotensinogen expression in SHR
cardiomyocytes, both at baseline conditions and after CT-1
incubation, are in accordance with the over-activation of this
signaling pathway and its final effect in this experimental model.
Moreover, the observation that the AT1 antagonist losartan inhibits
all the specific effects that CT-1 exerts in SHR cardiomyocytes
strongly reinforces the possibility that a cross-talk with the renin–
angiotensin systemmediates the distinct hypertrophic effects ofCT-
1 in cardiomyocytes with hypertensive phenotype, via an
exaggerated induction of angiotensinogen expression which may
lead to the participation of angiotensin II in cell growth. This
hypothesis is further supported by previous evidences showing that
the octepeptide increases cardiomyocyte width, enhances MLC-2v
and skeletal α-actin expression in isolated cardiomyocytes [27,30]
and promotes MLC-2v phosphorylation both in vitro and in vivo
[35].
At the structural level, the increase in cardiomyocyte length
results from the addition of sarcomeres in series and is
characteristic of volume overload cardiac hypertrophy [39],
whereas the insertion of new sarcomeric units in parallel
produces the transverse enlargement of cardiomyocytes present
in pressure overload hypertrophy [40]. Moreover, normal
myocardial levels of skeletal α-actin have been reported in
volume overload states, whereas pressure overload seems to be
associated with enhanced levels of this fetal protein [41,42].
Present findings in Wistar adult cells reinforce conceit that the
cell growth induced by CT-1 in normal cardiomyocytes
resembles volume overload hypertrophy. However, recent
experimental [5,14] and clinical [5,6] evidence indicates that
CT-1 may be involved in hypertensive LVH. Our ex vivo data
show for the first time a temporal association between the
increase in myocardial CT-1 expression (mRNA and protein)
and cardiomyocyte widening during the development of
concentric LVH in SHR, reinforcing a role for this cytokine in
hypertrophy that accounts in genetic hypertension. In addition,
present in vitro data provide a molecular explanation to
understand how the specific hypertensive phenotype of SHR
cardiomyocytes determines their distinct response to growth
factors such as CT-1.
In summary, we demonstrate for the first time that CT-1 exerts
specific hypertrophic effects in cardiomyocytes from SHRcompared to cardiomyocytes from adult Wistar rats, namely: the
increase in cell width, the increase in MLC-2v and skeletal α-
actin expression and the enhanced phosphorylation of MLC-2v.
Our data suggest that the molecular origin of this differential
effect is downstream STAT3 pathway activation and involve the
over-induction of rennin–angiotensin system. We also show an
association of enhanced myocardial CT-1 expression with
cardiomyocyte transverse growth and concentric LVH in SHR.
This observation strengthens a potential role for this cytokine in
the pressure overload hypertrophy that develops this genetic
model of hypertension and, likely, in essential hypertension. We
conclude that CT-1-induced hypertrophy critically depends on
cardiomyocyte hypertensive phenotype. Future studies modify-
ing myocardial CT-1 expression should confirm the pathoge-
netic involvement of the cytokine in hypertensive heart disease.
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